Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Type 2 diabetes is a national epidemic. Diabetes has undesirable effects on blood vessels
which may contribute to heart disease. Endothelial Progenitor Cells(EPCs) are found in the
blood . Research has shown that improving the survival of these special blood cells may
decrease the harmful effects of diabetes on blood vessels and reduce or reverse heart
disease. Saxagliptin is an FDA(Food and Drug Administration) approved prescription medicine
used along with diet and exercise to lower blood sugar in people with Type 2 diabetes. It is
in a class of diabetes medication called DPP-4 inhibitors. DPP-4 inhibitors have been shown
to increase EPCs in patients with Type 2 diabetes.
Hypothesis: We believe poor viability and function of EPCs in early diabetes ultimately
affects the repair and regeneration of the endothelium and that prompt intervention using
saxagliptin with another oral hypoglycemic agent, Metformin, may reduce or reverse
cardiovascular risk by improving EPC survival and function above and beyond adequate glucose
metabolism control.